Drug Trial Radar · NCT02714010
EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC
Last checked: Nov 19, 2026Latest source record: Oct 27, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
601
Planned (sponsor's estimate)
Start
Aug 2015
Primary completion
Dec 2021
Study completion Dec 2022
Sponsor
- Lead sponsor
- Sun Yat-sen UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 21, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center phase III randomized controlled study, designing to access whether the efficacy of EGFR-TKI alone on patients with brain metastasis from non-small cell lung cancer (NSCLC) harboring EGFR mutant type is not inferior to EGFR-TKI concurrent with whole brain radiotherapy (WBRT), the primary end point is intracranial PFS (iPFS), while secondary outcomes included overall survival (OS), objective response rate (ORR), evaluation of cognitive function, quality of life (QoL) and adverse events.
Conditions
- Non-Small Cell Lung Cancer
Interventions
EGFR-TKIDrug
Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid
whole brain radiotherapyRadiation
30Gy/10F
Primary outcomes
What the sponsor says the trial is designed to measure.
- intracranial PFS (iPFS)Time frame: up to 41 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University of cancer center
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.